A carregar...
Ezetimibe, cardiovascular risk and atherogenic dyslipidaemia
Ezetimibe is a selective cholesterol absorption inhibitor with an excellent side-effect profile, able to reduce low-density lipoprotein (LDL) cholesterol by 15-25% from baseline in monotherapy and on top of statins and fibrates. Yet, it seems that ezetimibe produces quantitative rather than qualitat...
Na minha lista:
| Main Authors: | , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Termedia Publishing House
2011
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3258692/ https://ncbi.nlm.nih.gov/pubmed/22291726 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.5114/aoms.2011.20597 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|